Sunesis Pharmaceuticals, Inc. (SNSS) Receives Average Rating of “Hold” from Analysts

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) have earned a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.16.

A number of equities research analysts have recently weighed in on the stock. Oppenheimer assumed coverage on shares of Sunesis Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $7.00 price objective on the stock. Cantor Fitzgerald set a $3.00 price target on shares of Sunesis Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, December 5th. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research note on Thursday, August 24th. Wells Fargo & Company upgraded shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price target for the stock from $2.86 to $2.48 in a research note on Monday, December 11th. Finally, Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Thursday, November 2nd.

Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $3.36 on Friday. The company has a debt-to-equity ratio of -0.34, a current ratio of 1.84 and a quick ratio of 1.84. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $4.45.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.06). During the same quarter last year, the business posted ($0.62) EPS. analysts forecast that Sunesis Pharmaceuticals will post -1.58 EPS for the current fiscal year.

In other news, Director Dayton Misfeldt bought 400,000 shares of the stock in a transaction dated Friday, October 27th. The shares were acquired at an average price of $2.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Mpm Oncology Impact Management bought 81,500 shares of the stock in a transaction dated Monday, November 6th. The stock was purchased at an average cost of $2.77 per share, for a total transaction of $225,755.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 506,800 shares of company stock worth $1,091,282. 10.21% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of SNSS. Renaissance Technologies LLC boosted its holdings in shares of Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. boosted its holdings in Sunesis Pharmaceuticals by 54.6% during the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 68,212 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Sunesis Pharmaceuticals by 77.4% during the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 18,254 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after buying an additional 23,819 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in Sunesis Pharmaceuticals during the second quarter worth about $208,000. 38.43% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/16/sunesis-pharmaceuticals-inc-snss-receives-average-rating-of-hold-from-analysts.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply